Cargando…
YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer
Small cell lung cancer (SCLC) is a highly aggressive and metastatic malignancy that shows rapid development of chemoresistance and a high rate of recurrence. Recent genome and transcriptome studies have provided the whole landscape of genomic alterations and gene expression changes in SCLC. In light...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198951/ https://www.ncbi.nlm.nih.gov/pubmed/27627196 http://dx.doi.org/10.1111/cas.13078 |
_version_ | 1782488918023733248 |
---|---|
author | Horie, Masafumi Saito, Akira Ohshima, Mitsuhiro Suzuki, Hiroshi I. Nagase, Takahide |
author_facet | Horie, Masafumi Saito, Akira Ohshima, Mitsuhiro Suzuki, Hiroshi I. Nagase, Takahide |
author_sort | Horie, Masafumi |
collection | PubMed |
description | Small cell lung cancer (SCLC) is a highly aggressive and metastatic malignancy that shows rapid development of chemoresistance and a high rate of recurrence. Recent genome and transcriptome studies have provided the whole landscape of genomic alterations and gene expression changes in SCLC. In light of the inter‐individual heterogeneity of SCLC, subtyping of SCLC might be helpful for prediction of therapeutic response and prognosis. Based on the transcriptome data of SCLC cell lines, we undertook transcriptional network‐defined SCLC classification and identified a unique SCLC subgroup characterized by relatively high expression of Hippo pathway regulators Yes‐associated protein (YAP) and transcriptional coactivator with PDZ‐binding motif (TAZ) (YAP/TAZ subgroup). The YAP/TAZ subgroup displayed adherent cell morphology, lower expression of achaete‐scute complex homolog 1 (ASCL1) and neuroendocrine markers, and higher expression of laminin and integrin. YAP knockdown caused cell morphological alteration reminiscent of floating growth pattern in many SCLC cell lines, and microarray analyses revealed a subset of genes regulated by YAP, including Ajuba LIM protein (AJUBA). AJUBA also contributed to cell morphology regulation. Of clinical importance, SCLC cell lines of the YAP/TAZ subgroup showed unique patterns of drug sensitivity. Our findings shed light on a subtype of SCLC with YAP and TAZ expression, and delineate molecular networks underlying the heterogeneity of SCLC. |
format | Online Article Text |
id | pubmed-5198951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-51989512016-12-30 YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer Horie, Masafumi Saito, Akira Ohshima, Mitsuhiro Suzuki, Hiroshi I. Nagase, Takahide Cancer Sci Original Articles Small cell lung cancer (SCLC) is a highly aggressive and metastatic malignancy that shows rapid development of chemoresistance and a high rate of recurrence. Recent genome and transcriptome studies have provided the whole landscape of genomic alterations and gene expression changes in SCLC. In light of the inter‐individual heterogeneity of SCLC, subtyping of SCLC might be helpful for prediction of therapeutic response and prognosis. Based on the transcriptome data of SCLC cell lines, we undertook transcriptional network‐defined SCLC classification and identified a unique SCLC subgroup characterized by relatively high expression of Hippo pathway regulators Yes‐associated protein (YAP) and transcriptional coactivator with PDZ‐binding motif (TAZ) (YAP/TAZ subgroup). The YAP/TAZ subgroup displayed adherent cell morphology, lower expression of achaete‐scute complex homolog 1 (ASCL1) and neuroendocrine markers, and higher expression of laminin and integrin. YAP knockdown caused cell morphological alteration reminiscent of floating growth pattern in many SCLC cell lines, and microarray analyses revealed a subset of genes regulated by YAP, including Ajuba LIM protein (AJUBA). AJUBA also contributed to cell morphology regulation. Of clinical importance, SCLC cell lines of the YAP/TAZ subgroup showed unique patterns of drug sensitivity. Our findings shed light on a subtype of SCLC with YAP and TAZ expression, and delineate molecular networks underlying the heterogeneity of SCLC. John Wiley and Sons Inc. 2016-11-25 2016-12 /pmc/articles/PMC5198951/ /pubmed/27627196 http://dx.doi.org/10.1111/cas.13078 Text en © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Horie, Masafumi Saito, Akira Ohshima, Mitsuhiro Suzuki, Hiroshi I. Nagase, Takahide YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer |
title | YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer |
title_full | YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer |
title_fullStr | YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer |
title_full_unstemmed | YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer |
title_short | YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer |
title_sort | yap and taz modulate cell phenotype in a subset of small cell lung cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198951/ https://www.ncbi.nlm.nih.gov/pubmed/27627196 http://dx.doi.org/10.1111/cas.13078 |
work_keys_str_mv | AT horiemasafumi yapandtazmodulatecellphenotypeinasubsetofsmallcelllungcancer AT saitoakira yapandtazmodulatecellphenotypeinasubsetofsmallcelllungcancer AT ohshimamitsuhiro yapandtazmodulatecellphenotypeinasubsetofsmallcelllungcancer AT suzukihiroshii yapandtazmodulatecellphenotypeinasubsetofsmallcelllungcancer AT nagasetakahide yapandtazmodulatecellphenotypeinasubsetofsmallcelllungcancer |